“Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01% Tazarotene 0.045% Lotion”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 6, Oct. 2020, p. s79, https://doi.org/10.25251/skin.4.supp.79.